Stevanato Group, an Italian company that makes glass vials for COVID-19 vaccines, is expected to conduct an initial public offering in the United States. Few details have been made public, but we'll update this page as new information emerges.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $18.27 |
|---|---|
| 52-week range | $16.56 - $34.63 |
| 50-day moving average | $19.62 |
| 200-day moving average | $23.32 |
| Wall St. target price | $26.47 |
| PE ratio | 44.5652 |
| Dividend yield | $0.053 (0.28%) |
| Earnings per share (TTM) | $0.46 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $18.15 from 2024-11-19
| 1 week (2024-11-14) | -11.46% |
|---|---|
| 1 month (2024-10-21) | -0.27% |
| 3 months (2024-08-21) | -5.52% |
| 6 months (2024-05-21) | -5.76% |
| 1 year (2023-11-21) | -32.48% |
|---|---|
| 2 years (2022-11-21) | 25.45% |
| 3 years (2021-11-19) | 22.8244 |
| 5 years (2019-11-18) | N/A |
Valuing Stevanato Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Stevanato Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Stevanato Group's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Stevanato Group shares trade at around 45x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Stevanato Group's P/E ratio is best considered in relation to those of others within the medical instruments & supplies industry or those of similar companies.
Stevanato Group's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.5691. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Stevanato Group's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Stevanato Group's PEG ratio in relation to those of similar companies.
Stevanato Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $230.4 million.
The EBITDA is a measure of a Stevanato Group's overall financial performance and is widely used to measure a its profitability.
To put Stevanato Group's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 14.99% |
| Gross profit TTM | $319.8 million |
| Return on assets TTM | 4.97% |
| Return on equity TTM | 9.48% |
| Profit margin | 10.48% |
| Book value | $4.85 |
| Market Capitalization | $5.6 billion |
TTM: trailing 12 months
Dividend payout ratio: 12.07% of net profits
Recently Stevanato Group has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Stevanato Group shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Stevanato Group's case, that would currently equate to about $0.053 per share.
While Stevanato Group's payout ratio might seem low, this can signify that Stevanato Group is investing more in its future growth.
Stevanato Group's most recent dividend payout was on 14 July 2024. The latest dividend was paid out to all shareholders who bought their shares by 3 June 2024 (the "ex-dividend date").
Stevanato Group's dividend payout ratio is perhaps best considered in relation to those of similar companies.
Over the last 12 months, Stevanato Group's shares have ranged in value from as little as $16.56 up to $34.6303. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Stevanato Group's is 0.584. This would suggest that Stevanato Group's shares are less volatile than average (for this exchange).
To put Stevanato Group's beta into context you can compare it against those of similar companies.
Stevanato Group S. p. A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.